Capmatinib latest price in 2024

Capmatinib is a targeted drug used to treat lung cancer and belongs to a class of drugs called tyrosine kinase inhibitors. It is designed to target a specific type of molecular abnormality in lung cancer, the overexpression or abnormal activation of the MET protein.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

METproteins usually regulate processes such as cell growth, differentiation, and migration in normal cells. However, in some cancers, the MET pathway may be abnormal, leading to abnormal growth and spread of cancer cells. By inhibiting the activity of MET kinase, capmatinib can interfere with the growth signaling of cancer cells, thereby inhibiting the development of lung cancer.

The clinical application of capmatinib is mainly concentrated in non-small cell lung cancer (NSCLC), especially those patients with MET gene mutations or MET overexpression. This drug is often used as a first-line or later-line treatment option, especially for patients who cannot obtain satisfactory results from traditional radiotherapy or chemotherapy. It has important clinical value.

In patients treated with capmatinib, doctors often individualize treatment based on the patient's genotype and the molecular characteristics of the cancer to maximize treatment effectiveness and reduce adverse effects. The use of drugs may be accompanied by some side effects, such as fatigue, nausea, abnormal liver function, etc., so the patient's physical condition needs to be closely monitored during treatment.